Our team of researchers include over 500+ competent individuals, who are stationed at our Six different R&D centres located in India and USA. Together, they power our enviable expertise in developing generics, transdermal drug delivery systems, oral films, difficult-to-produce technology intensive products and Novel Drug Delivery Systems (NDDS). We have dedicated teams for process development and packaging development.

We forayed into the R&D territory back in the year 2003. Our first R&D for ANDA development was setup in Taloja, Navi Mumbai, which is equipped with a wide range of state-of-the-art equipment.

Our research strategy and implementation is strongly supported by our proficient Intellectual Property (IP) team. Our IP team commands a strong expertise and hold rich experience in chemistry, analytical techniques, dosage forms and global patent law. Over the last decade, we have been consistently challenging patents on several high-value products in the US with First-to-File exclusivity under Hatch-Waxman Act. This helps us in furnishing high-quality generic versions of such products at reasonable costs. Our IP team continuously strives to capture new developments across the company and protects them as an intellectual property.

Our R&D centres have been audited and approved by international regulatory authorities, including the US FDA, European, Australian and various other authorities.